Abstract 253: Antitumor activity of PARP inhibitors in combination with Temozolomide in fumarate hydratase-deficient RCC.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institutions: National Institutes of Health, National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148737526
Cites:
Cited by:
Related to: